The PRKCG Gene Spinocerebellar Ataxia Type 14 Autosomal Dominant Genetic Test is a specialized diagnostic procedure designed to identify mutations in the PRKCG gene, which are known to cause Spinocerebellar Ataxia Type 14 (SCA14). SCA14 is a form of spinocerebellar ataxia, a neurodegenerative disorder characterized by progressive problems with movement, coordination, and balance, due to degeneration of the cerebellum and its connections. It is inherited in an autosomal dominant manner, meaning a mutation in just one of the two copies of the gene in each cell is sufficient to cause the disorder.
This test is particularly crucial for individuals with a family history of SCA14, displaying symptoms of the condition, or couples planning to have children and wanting to assess the risk of passing the condition onto their offspring. By analyzing the DNA to detect mutations in the PRKCG gene, this test can confirm a diagnosis of SCA14, assist in the management and treatment of the condition, and provide essential information for genetic counseling.
The test is offered by DNA Labs UAE, a facility known for its state-of-the-art genetic testing services. The cost of the PRKCG Gene Spinocerebellar Ataxia Type 14 Autosomal Dominant Genetic Test is 4400 AED. Given the complexity of the condition and the implications of the test results, individuals are often advised to undergo genetic counseling before and after the test to fully understand the potential outcomes and their impact.
The ITPR1 gene plays a crucial role in the proper functioning of the cerebellum, a part of the brain responsible for coordinating movement. Mutations in this gene can lead to Spinocerebellar Ataxia Type 15 (SCA15), a genetic disorder characterized by progressive deterioration of motor skills, balance issues, and coordination difficulties. The ITPR1 Gene Spinocerebellar Ataxia Type 15 Genetic Test is a specialized diagnostic tool designed to detect mutations in the ITPR1 gene, confirming the diagnosis of SCA15. This test is particularly valuable for individuals showing symptoms of ataxia or those with a family history of the condition, as it can provide definitive genetic evidence of SCA15.
Conducted by DNA Labs UAE, a leading facility in genetic testing, the test offers a comprehensive analysis of the ITPR1 gene. The cost of the test is set at 4400 AED, reflecting the intricate technology and expertise required to accurately identify mutations associated with the condition. By opting for this test, patients and their families can gain crucial insights into their genetic makeup, enabling informed decisions about management and treatment options for Spinocerebellar Ataxia Type 15.
The TBP Gene Spinocerebellar Ataxia Type 17 (SCA17) Autosomal Dominant Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in the TBP gene, which are responsible for causing SCA17. This condition is a form of spinocerebellar ataxia characterized by progressive degeneration of the cerebellum and other regions of the brain, leading to symptoms such as uncoordinated movements, balance problems, and difficulties with speech. The test is crucial for individuals with a family history of SCA17 or those exhibiting symptoms, as it helps in confirming the diagnosis, enabling early intervention and management strategies.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient's DNA sample, typically obtained from a blood draw, to identify the specific trinucleotide repeat expansion in the TBP gene that causes SCA17. The presence of an abnormal number of repeats confirms the diagnosis of SCA17.
The cost of the TBP Gene Spinocerebellar Ataxia Type 17 Autosomal Dominant Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated nature of the testing process, including the use of advanced genetic sequencing technologies and the expertise required to interpret the results accurately. For individuals at risk, this test provides invaluable information that can guide treatment decisions and genetic counseling, offering insights into the likelihood of passing the condition on to future generations.
The CWF19L1 gene test for Spinocerebellar Ataxia Type 17 (SCA17) is a specialized genetic test designed to detect mutations in the CWF19L1 gene, which have been associated with the development of this particular form of spinocerebellar ataxia. SCA17 is a rare, autosomal recessive neurodegenerative disorder characterized by a combination of cerebellar ataxia, which affects coordination and balance, along with other potential neurological symptoms. This condition is caused by genetic mutations, and identifying these mutations can be crucial for accurate diagnosis, family planning, and understanding the risk of transmission to offspring.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test offers a comprehensive analysis of the CWF19L1 gene to identify mutations that could lead to SCA17. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately.
Given the autosomal recessive inheritance pattern of the condition tested for, both copies of the gene in an individual must carry the mutation for the person to manifest symptoms of SCA17. This means that carriers, with only one mutated gene, do not typically show symptoms but can pass the mutated gene to their offspring.
Choosing to undergo this test at DNA Labs UAE ensures access to cutting-edge genetic testing technology, along with the support of genetic counselors and specialists who can provide comprehensive advice and interpretation of the test results, guiding patients through the complexities of genetic information and its implications for their health and family planning decisions.
The IFRD1 gene plays a crucial role in the genetic landscape of Spinocerebellar Ataxia Type 18 (SCA18), a rare, autosomal dominant neurological disorder characterized by impaired coordination and balance due to cerebellar degeneration. Individuals with mutations in the IFRD1 gene may exhibit symptoms such as unsteady gait, speech difficulties, and involuntary eye movements, which typically emerge due to the progressive nature of the disease.
To identify the presence of genetic mutations associated with SCA18, DNA Labs UAE offers a specialized genetic test targeting the IFRD1 gene. This test is pivotal for individuals with a family history of SCA18 or those exhibiting symptoms suggestive of the condition, providing a definitive diagnosis and enabling informed decisions regarding management and family planning.
The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory for mutations in the IFRD1 gene. The process is conducted with utmost confidentiality and accuracy, ensuring reliable results for patients and their families.
The GRID2 gene is associated with Spinocerebellar Ataxia Type 18 (SCA18), a rare genetic disorder characterized by progressive coordination and balance problems due to degeneration of the cerebellum. This condition is inherited in an autosomal recessive manner, meaning that an individual must receive a defective gene from each parent to be affected.
Testing for mutations in the GRID2 gene is crucial for diagnosing SCA18, enabling accurate genetic counseling, and facilitating management plans for affected individuals. The genetic test involves analyzing DNA to identify mutations in the GRID2 gene that are known to cause the disorder.
At DNA Labs UAE, a specialized test for the GRID2 gene associated with Spinocerebellar Ataxia Type 18 is available, helping in the early diagnosis and management of the condition. The cost of the test is 4400 AED. This comprehensive testing service provides vital information for affected families, offering insights into the genetic basis of the condition and the risk of passing it on to future generations.
The ATXN2 gene spinocerebellar ataxia type 2 (SCA2) autosomal dominant genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ATXN2 gene, which are known to cause spinocerebellar ataxia type 2. This condition is a neurodegenerative disorder characterized by progressive coordination problems, difficulty walking, and other neurological symptoms due to degeneration of the cerebellum and its connections. Since SCA2 is inherited in an autosomal dominant manner, having just one copy of the altered gene is sufficient to cause the disorder.
The test is crucial for individuals with a family history of SCA2 or those exhibiting symptoms suggestive of the condition. Early detection through genetic testing can aid in the management of symptoms, genetic counseling, and informing family planning decisions. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to detect mutations in the ATXN2 gene.
DNA Labs UAE offers this genetic test, providing a comprehensive analysis for those at risk of or suspected to have spinocerebellar ataxia type 2. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the expertise required to interpret the results accurately. Conducted in a state-of-the-art facility, the test adheres to high standards of quality and confidentiality, ensuring reliable and secure results for patients and their families.
The TMEM240 Gene Spinocerebellar Ataxia Type 21 Autosomal Dominant Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE. This test is designed to identify mutations in the TMEM240 gene, which have been linked to Spinocerebellar Ataxia Type 21 (SCA21), a rare genetic disorder. SCA21 is characterized by progressive coordination problems, difficulty walking, and other neurological symptoms due to cerebellar atrophy. As an autosomal dominant condition, having just one copy of the mutated gene from either parent is sufficient to cause the disorder.
The genetic test involves analyzing the patient's DNA to check for specific mutations in the TMEM240 gene that are responsible for SCA21. Early diagnosis through genetic testing can be crucial for the management of symptoms and understanding the risk of transmission to future generations.
DNA Labs UAE offers this comprehensive genetic test at a cost of 4400 AED. Conducted in a state-of-the-art laboratory setting, the test provides individuals and families with critical information regarding the genetic basis of SCA21, enabling informed decisions about health and family planning.
The KCND3 gene spinocerebellar ataxia type 22 autosomal dominant genetic test is a specialized diagnostic tool designed to identify mutations in the KCND3 gene, which are linked to the development of spinocerebellar ataxia type 22 (SCA22). SCA22 is a neurological condition characterized by progressive ataxia, which includes difficulties with coordination and balance due to cerebellar degeneration. As an autosomal dominant disorder, a mutation in just one of the two copies of the gene in each cell is sufficient to cause the condition, meaning it can be directly passed from an affected parent to their child.
The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in a laboratory setting to detect mutations in the KCND3 gene. This genetic testing is crucial for individuals with a family history of SCA22 or those exhibiting symptoms, as it can confirm a diagnosis, inform treatment decisions, and help with family planning.
Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the cost of the KCND3 gene spinocerebellar ataxia type 22 autosomal dominant genetic test is set at 4400 AED. This investment in testing is essential for those seeking clarity on their genetic status concerning SCA22, enabling them and their healthcare providers to make informed decisions regarding their health and future.
The PDYN gene Spinocerebellar Ataxia Type 23 (SCA23) Autosomal Dominant Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the PDYN gene that are associated with SCA23. Spinocerebellar ataxia type 23 is a neurodegenerative disorder characterized by progressive problems with movement, typically emerging in adulthood. The condition is inherited in an autosomal dominant pattern, meaning that a mutation in just one copy of the relevant gene in each cell is sufficient to cause the disorder.
The test involves analyzing the patient's DNA to look for specific genetic changes in the PDYN gene that are known to cause SCA23. This genetic testing is crucial for the accurate diagnosis of the condition, which can help in planning the appropriate management and treatment strategies for affected individuals. Additionally, it can provide essential information for family planning and genetic counseling for families affected by SCA23.
At DNA Labs UAE, the cost of the PDYN gene Spinocerebellar Ataxia Type 23 Autosomal Dominant Genetic Test is set at 4400 AED. This comprehensive testing service not only offers a crucial diagnostic tool for patients and their families but also provides the peace of mind that comes with understanding one's genetic health landscape.
